Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma

Immunotherapies blocking negative immune checkpoints are now approved for the treatment of a growing number of cancers. However, even in metastatic melanoma, where sustained responses are observed, a significant number of patients still do not respond or display resistance. Increasing evidence indic...

Descripción completa

Detalles Bibliográficos
Autores principales: Benboubker, Valentin, Boivin, Félix, Dalle, Stéphane, Caramel, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012258/
https://www.ncbi.nlm.nih.gov/pubmed/35432344
http://dx.doi.org/10.3389/fimmu.2022.873116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012258/
https://www.ncbi.nlm.nih.gov/pubmed/35432344
http://dx.doi.org/10.3389/fimmu.2022.873116

Ejemplares similares